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Aortic flow propagation velocity, epicardial fat thickness, and 
osteoprotegerin level to predict subclinical atherosclerosis in patients 
with nonalcoholic fatty liver disease
Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common 
cause of liver dysfunction in Western countries. Additionally, it is 
an independent risk factor for atherosclerotic heart disease (1). 
Several noninvasive markers for atherosclerotic heart disease 
have recently been discovered, including epicardial fat thick-
ness (EFT), aortic flow propagation velocity (APV), and osteopro-
tegerin (OPG) level (2–4). 
Aortic distensibility and aortic strain are elasticity indices 
that reflect aortic stiffness. Impaired aortic distensibility has 
been related to increased cardiovascular mortality in different 
populations (5, 6). APV, which is also used to evaluate aortic stiff-
ness, might be an indicator of the presence of atherosclerotic 
heart disease. Another echocardiographic marker for athero-
sclerotic heart disease is EFT. Human epicardial adipose tissue 
is described as a potential paracrine and/or endocrine tissue, 
specifically within the context of cardiovascular risk (7–9). OPG, 
a cytokine also known as osteoclastogenesis inhibitory factor, 
has been found to have a higher plasma concentration in pa-
tients with than without atherosclerotic heart disease (10–13). 
Several authors have concluded that OPG appears to be a prom-
ising biomarker of atherosclerosis that is independently associ-
ated with traditional risk factors of subclinical and clinical ath-
erosclerotic disease (14–16).
The aim of this study was to evaluate OPG, APV, and EFT for 
atherosclerotic heart disease in patients with NAFLD, which is 
an independent risk factor for atherosclerotic heart disease.
Objective: Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in Western countries and an independent risk factor 
for atherosclerotic heart disease. Appropriate noninvasive parameters are lacking for optimal risk stratification of cardiovascular disease in 
these patients. We evaluated several recently discovered noninvasive parameters for atherosclerosis in patients with nonalcoholic fatty liver 
disease: epicardial fat thickness, aortic flow propagation velocity, and osteoprotegerin level.
Methods: Forty-one patients (27 men and 14 women; mean age, 37.9±8.9 years) with nonalcoholic fatty liver disease and 37 control subjects (17 
men and 20 women; mean age, 34.5±8.6 years) were enrolled in this observational case-control study. Patients with nonalcoholic fatty liver dis-
ease diagnosed at a gastroenterology outpatient clinic were included. Patients with cardiac pathology other than hypertension were excluded. 
Epicardial fat thickness and aortic flow propagation velocity were measured by echocardiography. The serum concentration of osteoprotegerin 
was measured using a commercial enzyme-linked immunosorbent assay kit.
Results: Nonalcoholic fatty liver disease patients exhibited a significantly lower aortic flow propagation velocity (155.17±30.00 vs. 179.00±18.14 
cm/s, p=0.000) and significantly higher epicardial fat thickness (0.51±0.25 vs. 0.29±0.09 cm, p=0.000) than control subjects. Osteoprotegerin 
levels were higher, but not significant, in patients with nonalcoholic fatty liver disease (28.0±13.0 vs. 25.2±10.8 pg/mL, p=0.244). Binary logistic 
regression analysis showed that aortic flow propagation velocity (OR, –0.973; 95% CI, 0.947–0.999) and waist circumference (OR, –1.191; 95% CI, 
1.088–1.303) were independent predictors of nonalcoholic fatty liver disease.
Conclusion: In this study, epicardial fat thickness and osteoprotegerin level were higher and aortic flow propagation velocity was lower in pa-
tients with nonalcoholic fatty liver disease. Early detection of abnormal epicardial fat thickness and aortic flow propagation velocity may warrant 
a search for undetected cardiovascular disease in patients with nonalcoholic fatty liver disease. (Anatol J Cardiol 2016; 16: 974-9)
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Methods
Study population 
In total, 41 patients with NAFLD (27 men and 14 women; mean 
age, 37.9±8.9 years) and 37 control subjects (17 men and 20 women; 
mean age, 34.5±8.6 years) were enrolled in this observational case-
control study. The patients had been consecutively observed at our 
gastroenterology outpatient clinic over the past 12 months. Liver ul-
trasound (US) examinations were performed to assess the degree 
of steatosis. All US scans were performed by the same operator, 
who was blinded to the patients’ clinical status. The exclusion cri-
teria were coronary artery disease; a positive treadmill exercise 
test result; diabetes mellitus; a body mass index (BMI) of >35 kg/
m2; bundle branch block; paced rhythm; atrial fibrillation; Q waves; 
left ventricular hypertrophy or strain on the electrocardiogram at 
rest; significant valvular heart disease; congenital heart disease; 
aortic aneurysm; systemic diseases that affect the aorta; severe 
obstructive pulmonary disease; chronic renal disease; treatment 
with estrogen, amiodarone, steroids, tamoxifen, diltiazem, or herb-
als; history of abdominal surgery; history or suspicion of viral hepa-
titis; and a daily alcohol intake exceeding 20 g/day. All participants 
included in the control group were judged to have normal results 
on liver function tests and were confirmed to have a normal liver by 
US scanning. All participants provided informed written consent. 
The study protocol conformed with the Declaration of Helsinki. 
Anthromorphometry, blood pressure measurement, 
and laboratory testing
All participants underwent physical examination, anthro-
pometric measurements, and biochemical screening. BMI was 
defined as weight (in kilograms) divided by the square of the 
height (in meters). Waist circumference (in centimeters) was 
recorded as the average of two measurements at the midpoint 
between the lowest rib and the iliac crest while the participant 
was standing. Blood pressure was measured using a mercury 
sphygmomanometer in a quiet room after at least 10 min of rest. 
The average of three measurements was used. Blood samples 
were obtained after 12 h of fasting. The levels of low-density li-
poprotein cholesterol (LDL), high-density lipoprotein cholesterol 
(HDL), triglyceride, total cholesterol, glucose, creatinine, hemo-
globin, aspartate aminotransferase, and alanine aminotransfer-
ase were measured by routine laboratory techniques. 
The serum concentration of OPG was measured using a com-
mercial enzyme-linked immunosorbent assay (ELISA) kit (model 
number: BMS2021 INST) (eBioscience, Vienna, Austria). Serum 
samples were collected and subsequently stored at –80°C un-
til OPG analysis. The investigator who analyzed the OPG serum 
concentrations was blinded to all clinical information. Both the 
monomeric and dimeric forms of OPG and OPG bound to RANKL 
were detected in this assay. A monoclonal IgG antibody was 
used as the capture antibody, and a biotin-conjugated polyclonal 
antihuman OPG antibody was used as the detection antibody. 
The detection limit of this assay system was 2.5 pg/mL; the intra-
assay and inter-assay coefficients of variation were typically 7% 
and 8%, respectively, at low and high concentrations of OPG. 
Transthoracic echocardiographic examination
Echocardiographic examination was performed at rest in 
the left lateral decubitus position. Measurements were ob-
tained using an Acuson Sequoia 512 system (Siemens, Munich, 
Germany) with a 4-MHz transducer according to the American 
Society of Echocardiography measurement guidelines. Echocar-
diographic evaluation was performed by the same experienced 
cardiologist who had no clinical information about the patients. 
The epicardial fat was defined as the echo-free space between 
the outer wall of the myocardium and the visceral layer of the 
pericardium. EFT was measured perpendicularly on the free wall 
of the right ventricle at end- diastole for three cardiac cycles. 
The aortic annulus was used as the anatomical landmark with 
which to standardize the measurement point. The average mea-
surement of three cardiac cycles was used for the statistical 
analysis. Color M-mode Doppler recordings were obtained from 
the suprasternal window in the supine position. The cursor was 
located parallel to the main fl ow direction in the descending 
aorta. The Nyquist limit was adapted to 30–50 cm/s, switching to 
the M-mode with the recorder sweep rate of 200 mm/s. The M-
mode spatiotemporal velocity map in the shape of a flame was 
displayed. If the slope of the flame was unclear, baseline shifting 
was used to change the aliasing velocity until a clear delinea-
tion of the velocity slope was obtained. APV was then calculated 
by dividing the distance between the points corresponding to 
the beginning and end of the propagation slope by the duration 
between the corresponding time points. Thus, APV corresponds 
to the velocity at which the flow is propagating down the artery. 
The mean of at least three measurements was recorded as APV.
Exercise electrocardiography
A symptom-limited treadmill exercise electrocardiographic 
test was performed with the modified Bruce protocol to distin-
guish lower risk of CVD patients more precisely. The test result 
was defined as positive if the horizontal or down-sloping ST-
segment depression measured ≥1 mm at 80 ms after the J point 
in two or more contiguous leads, and typical angina increased in 
severity with exercise.
Statistical analysis
Statistical analyses were performed using the Statistical 
Package for the Social Sciences (SPSS) software, version 18 
(SPSS Inc., Chicago, Illinois, USA). Statistical significance was 
defined as p<0.05. Results are given as mean±standard error 
(SE) and median [interquartile range (IQR)]. Variable distribu-
tions were assessed with the Kolmogorov–Smirnov normality 
test. Statistical comparison between groups was assessed by 
student’s t-test, the Mann–Whitney U test, or the Pearson chi-
square test. Correlation analyses were performed using Spear-
man or Pearson’s coefficients to assess relationships of mea-
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sures. Binary logistic regression analysis was used to determine 
the independent predictors of NAFLD.
Results
Forty-one patients with NAFLD (mean age, 37.9±8.9 years) 
and 37 controls (mean age, 34.5±8.6 years) participated in this 
study. The mean values for the main clinical and laboratory 
characteristics in the NAFLD and control groups are reported 
in Table 1. The age, sex distribution, diastolic blood pressure, 
heart rate, history of hypertension, medications, family history 
of coronary artery disease, and smoking ratio were similar be-
tween the NAFLD and control groups. Patients with NAFLD had 
significantly higher BMI, waist circumference, lipid profile, sys-
tolic blood pressure, fasting blood glucose, hemoglobin, and 
creatinine values than the controls (Table 1). The median value 
of EFT was 0.40 cm (0.36–0.55 cm) in patients with NAFLD and 
0.29 cm (0.23–0.33 cm) in controls, with a statistically significant 
difference (p<0.001) (Table 2). APV was 155.17±30.00 cm/s in pa-
tients with NAFLD and 179.40±18.14 cm/s in controls, with a sta-
tistically significant difference (p<0.001) (Table 2). The OPG level 
was higher in the NAFLD group than in the control group, but 
was statistically insignificant [25.1 pg/mL (21.06–28.6 pg/mL) and 
22.26 pg/mL (19.71–25.04 pg/mL) respectively; p=0.244] (Table 2). 
Among all patients, EFT was correlated with age (r=0.44, 
p<0.001), waist circumference (r=0.42, p<0.001), BMI (r=0.38, 
p=0.001), fasting blood glucose (r=0.48, p<0.001), total cholesterol 
(r=0.27, p=0.017), LDL (r=0.33, p=0.004), and triglycerides (r=0.28, 
p=0.013) (Table 3). However, there was no correlation among EFT, 
OPG, and HDL. 
APV was correlated with waist circumference (r=–0.27, 
p=0.02), BMI (r=–0.28, p=0.012), and fasting blood glucose (r=–
0.24, p=0.04) (Table 4).
We found a statistically significant correlation between EPF 
and APV (r=–0.313, p=0.006). Binary logistic regression analysis 
showed that APV (OR, –0.973; 95% CI, 0.947–0.999) and waist cir-
cumference (OR, –1.191; 95% CI, 1.088–1.303) were independent 
predictors of NAFLD.
Discussion
This study mainly evaluated the relationship between APV, 
EFT, and OPG levels as atherosclerotic parameters and NAFLD. 
We demonstrated increased EFT and OPG levels and decreased 
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Table 1. Clinical and biochemical characteristics of patients with 
nonalcoholic fatty liver disease and controls
  Controls Patients with NAFLD P 
  (n=37) (n=41) 
Gender, male/female, n 17/20 27/14 NS
Age, years 34.5±8.6 37.9±8.9 NS
BMI, kg/m2 24.20±3.26 29.50±3.97 <0.001
SBP, mm Hg 118.0±13.8 129.3±14.8 0.001
DBP, mm Hg 75.0±11.5 79.6±12.5 NS
Heart rate, beats/min 78.9±13.9 76.6±13.4 NS
Pulse pressure, mm Hg 43.0±10.6 49.2±12.3 0.020
Waist circumference, cm 89.5±9.7 106.0±11.9 <0.001
Smoking 13 15 NS
HT 3 9 NS
Anti-HT treatment 3 7 NS
Family history of CAD 7 5 NS
Hemoglobin, g/dL 13.77±1.40 15.0±1.20 <0.001
Creatinine, mg/dL 0.77±0.12 0.86±0.14 0.002
FBG, mg/dL 91.2±7.0 98.6±9.9 <0.001
LDL, mg/dL 118.0±33.0 140.7±40.3 0.009
HDL, mg/dL 49.0±9.9 39.7±8.9 <0.001
Total cholesterol, mg/dL 183.5±36.1 212.3±42.8 0.002
Triglycerides, mg/dL 87(75–101) 158(126–198) <0.001
BMI - body mass index; CAD - coronary artery disease; DBP - diastolic blood pres-
sure; FBG - fasting blood glucose; HDL - high-density lipoprotein cholesterol; HT 
- hypertension; LDL - low-density lipoprotein cholesterol; NAFLD - nonalcoholic fatty 
liver disease; NS - nonsignificant; SBP - systolic blood pressure. Student’s t-test or 
the Mann–Whitney U test was used for comparison of groups. Categorical variables 
were compared using the Pearson chi-square test
Table 2. Comparison of epicardial fat thickness, aortic flow 
propagation velocity, and osteoprotegerin level between 
nonalcoholic fatty liver disease and control groups
  Controls Patients with NAFLD P 
  (n=37) (n=41)
EFT, cm 0.29 (0.23–0.33) 0.40 (0.36–0.55) <0.001
APV, cm/s 179.40±18.14 155.17±30.00 <0.001
OPG, pg/mL 22.26 (19.71–25.04) 25.1 (21.06–28.6) 0.244
APV - aortic flow propagation velocity; EFT - epicardial fat thickness; NAFLD - nonal-
coholic fatty liver disease; OPG - osteoprotegerin. Binary logistic regression analysis 
was performed to assess the correlations between the studied parameters
Table 3. Correlation of epicardial fat thickness with clinical variables
  Correlation coefficient P
Age 0.44 <0.001
Waist circumference 0.42 <0.001
Body mass index 0.38 0.001
Fasting glucose 0.48 <0.001
Total cholesterol 0.27 0.017
LDL cholesterol 0.33 0.004
HDL cholesterol –0.19 0.930
Triglycerides 0.28 0.013
Osteoprotegerin 0.21 0.063
Hemoglobin 0.14 0.240
Correlation analyses were performed using Spearman or Pearson’s coefficients 
according to the distribution of the variables. HDL - high-density lipoprotein; LDL - 
low-density lipoprotein
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APV levels in patients with NAFLD. Moreover, we showed that 
APV was correlated with waist circumference, BMI, and fasting 
glucose; EFT was correlated with APV. 
NAFLD is a chronic liver disease that comprises a wide spec-
trum of hepatic damage ranging from simple steatosis and ste-
atohepatitis to advanced fibrosis and cirrhosis (17). Although the 
true prevalence of NAFLD is unknown, the estimated prevalence 
in the general population ranges from 3% to 24% (18). In the pres-
ent study, patients with NAFLD had a higher systolic blood pres-
sure, waist circumference, fasting blood glucose, and triglycer-
ide level and a lower HDL level. According to previous studies, 
NAFLD appears to be strongly associated with risk factors for 
atherosclerosis, such as hypertension, obesity, diabetes, high tri-
glycerides, low HDL, insulin resistance, and metabolic syndrome; 
NAFLD also appears to increase with age (18). Patients with 
NAFLD have an increased risk of cardiovascular disease (CVD) 
(19–21), reportedly independent of underlying cardiovascular risk 
factors (22). Efe et al. (23) found that the prevalence of coronary 
artery disease in patients with NAFLD was significantly higher 
than that in patients with normal liver tissue. The association 
between NAFLD and the risk of CVD has been attributed to in-
creased oxidative stress and subclinical inflammation. Fat depo-
sition in patients with NAFLD is considered to increase the levels 
of free fatty acids that lead to CVD by causing inflammation (24, 
25). Indeed, it is hypothesized that NAFLD is not only a risk marker 
of CVD but may also be involved in its pathogenesis (26). Genetic 
predisposition, reduced levels of adiponectin, and coagulation 
imbalance are the other physio-pathogenic mechanisms of CVD 
in NAFLD patients (27). Endothelial dysfunction is the first stage 
in the development of atherosclerosis and CVD. Atherosclerosis 
leads to increased arterial resistance through thickening and 
stiffening of the arterial wall. A loss of arterial elastic properties 
results in pathophysiological changes in circulation, including in-
creased pulse pressure and vessel endothelial dysfunction (28). 
Increased arterial resistance may be reflected by a decrease in 
APV. Güneş et al. (29) recently showed that the M-mode-derived 
propagation velocity of the descending thoracic aorta (AVP), 
which is an easy, practical, noninvasive measurement of arte-
rial resistance, was associated with coronary atherosclerosis. In 
the present study, AVP was lower in patients with NAFLD than in 
controls. Additionally, APV was correlated with waist circumfer-
ence, BMI, and fasting glucose. Increased aortic stiffness has 
been shown to be more closely related to visceral obesity, as 
assessed by waist circumference, than to an increased BMI (30). 
However, further studies are required to determine whether the 
measurement of AVP may be used to improve cardiovascular risk 
estimation in patients with NAFLD. EFT is clinically related to car-
diac and visceral adiposity, and it has been suggested as a new 
cardiometabolic risk factor (31). The epicardial fat tissue is in di-
rect contact with the myocardium and major coronary arteries 
and their branches and is metabolically active (32, 33). Epicardial 
adipocytes can secrete a large number of cytokines and vasoac-
tive peptides, all of which can independently increase cardiovas-
cular risk (34). Echocardiographic assessment of EFT is simple, 
rapid, safe, and easily reproducible and may have a potential to 
be a simple and reliable marker of increased cardiovascular risk. 
In the study of Eroğlu et al. (35), EFT was found to be a marker of 
the presence and severity of coronary artery disease. Iacobel-
lis et al. (36) found that EFT better predicts ultrasound-measured 
fatty liver than BMI or waist circumference in obese patients. In 
our study, we exclude morbid obese patients (BMI >35 kg/m2). 
Another study showed that a higher EFT is associated with the 
severity of liver fibrosis. They also found some alterations of car-
diac functions and morphology linked to liver fibrosis (37). How-
ever, in the study of Psychari et al. (38), EFT was not found to be 
significantly correlated with NAFLD. In contrast to these studies, 
in our study, we did not include high cardiovascular risk patients 
and showed that EFT is correlated with age, fasting glucose, total 
cholesterol, LDL, triglycerides, waist circumference, and BMI, in 
accordance with some previous findings (39, 40).
Moreover, our data showed that EFT was significantly higher 
in the NAFDL than in the control group. Furthermore, EFT was 
correlated with APV, which is a previously described marker of 
increased arterial resistance. In the study of Sünbül et al. (41), 
patients with NAFLD have increased arterial resistance. In ad-
dition, they found that the severity of liver fibrosis and EFT are 
independent predictors of measurements of arterial resistance. 
Numerous randomized controlled studies have found that 
OPG, a soluble decoy receptor of osteoclast activator, acts as a 
regulatory molecule in patients with vascular calcification. In the 
Women on the Move through Activity and Nutrition (WOMAN) 
study (42), a higher OPG was associated with a higher coronary 
artery calcium score, whereas the Framingham Study reported 
a nonsignificant relationship between OPG and coronary cal-
cification (12). The serum OPG level is associated with arterial 
stiffness, as measured by pulse wave velocity (43). Moreover, a 
high serum OPG level was reported to be an independent pre-
dictor of cardiovascular events in patients undergoing hemodi-
Table 4. Correlation of aortic flow propagation velocity with clinical variables
  Correlation coefficient P
Age –0.280 0.140
Waist circumference –0.270 0.020
Body mass index –0.280 0.012
Fasting glucose –0.240 0.040
Total cholesterol –0.020 0.880
LDL cholesterol 0.007 0.950
HDL cholesterol 0.220 0.059
Triglycerides –0.190 0.087
Osteoprotegerin –0.140 0.210
Hemoglobin 0.030 0.810
Correlation analyses were performed using Spearman or Pearson’s coefficients 
according to the distribution of the variables. HDL - high-density lipoprotein; LDL - 
low-density lipoprotein
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alysis (43). In addition, a 17-year prospective follow-up study of 
patients with type II diabetes showed a strong predictive value 
of the OPG level for all-cause and cardiovascular mortality (44). 
However, the present study showed that the OPG level was not 
significantly increased in patients with NAFLD. Moreover, there 
was no association between the OPG level and APV. This dis-
crepancy may be due to the small sample size of this study as 
well as the patients’ characteristics, which included younger 
ages and a more stable clinical status with a lower risk profile of 
CVD than in previous studies. 
Study limitations
Our study has several limitations. First, because the sam-
ple size was relatively small, only a few patients in the NAFLD 
group had upper-limit alanine aminotransferase levels, and the 
degree of steatosis was not assessed. Second, NAFLD was not 
confirmed by liver biopsy, and for medical and ethical reasons, 
we excluded alcoholic liver disease and autoimmune hepatitis 
based on answers to a simple questionnaire.
Conclusions
In this study, we demonstrated APV is independently associ-
ated with NAFLD, even those classified as being at low risk for 
cardiovascular events according to traditional risk scores. In ad-
dition, the present study showed that EFT was higher in patients 
with than without NAFLD. Early detection of abnormal EFT and 
APV levels may warrant a search for undetected CVD in patients 
with NAFLD.
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